Abstract: The present disclosure provides compounds that may be used as ligands in metal-catalyzed reactions, in particular 3,3?-bisilyl biaryl phosphoramidite compounds and processes for preparing the same.
Abstract: A compound including a first ligand LA of is disclosed. In the structure of Formula I, one of L1 and L2 is C, and the other is N; Y1 to Y14 are each C or N; at least two adjacent Y7, Y8, Y9, and Y10 are carbon atoms that are fused to a structure of Z1 and Z2 are each O, S, Se, NR, CRR?, or SiRR?; and each R, R?, RA, RB, RC, and RD is hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, LA is complexed to a metal M by L1 and L2, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.
Type:
Application
Filed:
November 29, 2023
Publication date:
May 9, 2024
Applicant:
UNIVERSAL DISPLAY CORPORATION
Inventors:
Zhiqiang LI, Jui-Yi TSAI, Alexey Borisovich DYATKIN, Chun LIN
Abstract: Embodiments in accordance with the present invention encompass an organoruthenium compound of the formula I: (I) wherein X, Y, L1, L2, L3, R1 and R2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of the formula I as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction.
Type:
Application
Filed:
February 2, 2022
Publication date:
May 9, 2024
Inventors:
Michal CHWALBA, Krzysztof SKOWERSKI, Konrad KURCBACH
Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.
Type:
Application
Filed:
May 19, 2023
Publication date:
May 9, 2024
Applicant:
CureVac SE
Inventors:
Stefan HEINZ, Tilmann ROOS, Dominik VAHRENHORST, Markus CONZELMANN
Abstract: A glucocerebroside compound, a pharmaceutical composition thereof, and the use of the glucocerebroside compound and the pharmaceutical composition thereof in the preparation of drugs for preventing or treating immune-related diseases.
Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.
Type:
Application
Filed:
November 7, 2023
Publication date:
May 9, 2024
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Indranath GHOSH, Jason NOGUEIRA
Abstract: The present invention relates to a compound according to Formula (1a) or (1b): wherein R1; R3; Y and X are defined herein, and their use in methods of nucleic acid synthesis.
Type:
Application
Filed:
February 21, 2022
Publication date:
May 9, 2024
Inventors:
Gordon Ross MCINROY, Martin Edward FOX, Puneet SRIVASTAVA, Michal Robert MATUSZEWSKI
Abstract: The purpose of the present invention is to provide a novel stereoselective method for preparing a cyclic dinucleotide derivative and a production intermediate therefor, which can be used for an antibody-immunostimulant conjugate. Also provided is a method for producing a cyclic dinucleotide-linker and an antibody-immunostimulant conjugate while using the above production method. Further provided is a method for preparing a cyclic dinucleotide derivative, the method including the step of subjecting a compound (I) and a compound (IV) to stereoselective condensation using an optically active phosphitylating agent (Rc-II) or (Sc-II).
Abstract: The present disclosure provides a solid phase method of making oligonucleotides via sequential coupling cycles including at least one coupling of a dinucleotide dimer subunit to a free 3?-terminal group of a growing chain. The oligonucleotides include at least two nucleoside subunits joined by a N3??P5? phosphoramidate linkage. The method may include the steps of (a) deprotecting the protected 3? amino group of a terminal nucleoside attached to a solid phase support, said deprotecting forming a free 3? amino group; (b) contacting the free 3? amino group with a 3?-protected amino-dinucleotide-5?-phosphoramidite dimer in the presence of a nucleophilic catalyst to form an internucleoside N3??P5? phosphoramidite linkage; and (c) oxidizing (e.g., sulfurizing) the linkage. The compositions produced by the subject methods may include a reduced amount of one or more (N-x) oligonucleotide products. Also provided are pharmaceutical compositions including the subject oligonucleotide compositions.
Abstract: Novel compositions and methods for engineering wireframe architectures and scaffolds of increasing complexity by creating gridiron-like DNA structures (FIG. 1). A series of four-arm junctions are used as vertices within a network of double-helical DNA fragments. Deliberate distortion of the junctions from their most relaxed conformations ensures that a scaffold strand can traverse through individual vertices in multiple directions. DNA gridirons, ranging from two-dimensional arrays with reconfigurability to multilayer and three-dimensional structures and curved objects, can be assembled according the methods presented herein.
Abstract: Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Type:
Application
Filed:
June 5, 2023
Publication date:
May 9, 2024
Inventors:
Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
Abstract: Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
Type:
Application
Filed:
May 23, 2023
Publication date:
May 9, 2024
Applicant:
PFIZER INC.
Inventors:
Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
Abstract: The present disclosure relates to methods and systems for the continuous production of recombinant proteins. In particular embodiments, the disclosure relates to methods and systems using capture chromatography, post-capture chromatography, virus filtration, and ultrafiltration/diafiltration for the continuous production of recombinant proteins.
Type:
Application
Filed:
January 18, 2024
Publication date:
May 9, 2024
Inventors:
Michael Coolbaugh, Tarl Vetter, Chad Varner, Kevin Brower
Abstract: Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.
Type:
Application
Filed:
March 3, 2022
Publication date:
May 9, 2024
Inventors:
Thomas D. Meek, Linfeng Li, Chien-Te Kent Tseng, Aleksandra Drelich
Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
Type:
Application
Filed:
October 28, 2022
Publication date:
May 9, 2024
Inventors:
Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
Abstract: The present invention provides peptides and conjugates thereof, as ACE-2 and S1 subunit mimicking peptides for the prevention and control of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2) infection by preventing the binding of Severe Acute Respiratory Syndrome Coronavirus-2 to the target cells.
Abstract: Provided are peptides that are derived from probiotic bacteria that have use for preventing and/or treating non-enteric infections in a subject. The peptides derived from the probiotic bacteria also have use for reducing the virulence of non-enteric infections in a subject. Also provided are compositions of the peptides formulated as or within food products, beverages, nutritional supplements, medicaments and the like.
Type:
Application
Filed:
January 15, 2024
Publication date:
May 9, 2024
Inventors:
Monica Angela Cella, Sarah M. Curtis, Jonathon Patrick Roepke
Abstract: The present invention relates to natural or natural-like analogues of insect kinin neuropeptide [Hy]-RQKTVFSSWG-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and/or blattodean insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.
Type:
Application
Filed:
October 23, 2023
Publication date:
May 9, 2024
Applicant:
Solasta Bio Limited
Inventors:
Julian A.T. Dow, Shireen A. Davies, Yousef Abul-Haija, Lewis Archibald
Abstract: The present invention relates to natural or natural-like analogues of insect kinin neuropeptide [Hy]-PAFSSWG-[NH2] (SEQ ID NO:2) having activity against insects, for example hemipteran, dipteran, lepidopteran and/or blattodean insects, such as aphids, moths and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.
Type:
Application
Filed:
October 23, 2023
Publication date:
May 9, 2024
Applicant:
Solasta Bio Limited
Inventors:
Julian A.T. Dow, Shireen A. Davies, Yousef Abul-Haija, Lewis Archibald
Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Application
Filed:
December 8, 2023
Publication date:
May 9, 2024
Inventors:
Stephen James MOORE, Margaret Thy Luu NGUYEN, Daniel Robert HOSTETTER, Olga VASILJEVA
Abstract: The Applicant has discovered that the peptide of SEQUENCE ID NO: 1 (WKDEAGKPLVK) mediates changes in key biomarker activities associated with NASH (Table 1), and that the peptide is capable of penetrating HepG2 liver cells in a hepatic cell penetration assay (FIG. 1). In addition, the Applicant demonstrates that treatment with pep_260 (SEQ ID 1) for 44 days significantly relieves macro-vesicular steatosis in obese diabetic KKAy mice (FIG. 2) In a first aspect, the invention relates to the use of a peptide comprising SEQUENCE ID NO: 1, or a functional (or therapeutically effective) variant or functional fragment of SEQUENCE ID NO: 1 (hereafter “peptide active agent” or “peptide of the invention”), in a method for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD), in particular non-alcoholic steatohepatitis (NASH), in a mammal.
Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.
Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Type:
Application
Filed:
October 23, 2023
Publication date:
May 9, 2024
Inventors:
Chengzao SUN, Brian Troy FREDERICK, Sandeep SOMANI, Gregory Thomas BOURNE, Raymond PATCH, Ashok BHANDARI, Raffaele INGENITO, Roberto COSTANTE, Danila BRANCA, Elisabetta BIANCHI
Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.
Type:
Application
Filed:
October 10, 2023
Publication date:
May 9, 2024
Inventors:
David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Michael Hamill, Rajeev Chillakuru, John F. Kramarczyk
Abstract: The present invention relates to: a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 to 7 or a fragment thereof; and a pharmaceutical composition for the treatment or prevention of inflammatory diseases or autoimmune diseases, comprising same. The peptide has been confirmed to have an excellent effect of inhibiting cytokines such as IL-17 and TNF alpha, and thus can be provided as a therapeutic agent for various inflammatory diseases, including Behcet's disease.
Abstract: Compositions and methods involving nanoligomers are disclosed herein. Nanoligomers may include a targeting sequence and a nanostructure. A targeting sequence may include a polynucleotide binding domain and a transcription activation domain. A nanostructure may include a nanoparticle and a cell uptake domain.
Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.
Abstract: Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased viral transduction in the CNS. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating CNS-related diseases and conditions.
Type:
Application
Filed:
April 13, 2022
Publication date:
May 9, 2024
Inventors:
Nicholas C. Flytzanis, Nicholas S. Goeden, Troy E. Sandberg, Brandon G. Wheeler
Abstract: Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.
Type:
Application
Filed:
June 20, 2023
Publication date:
May 9, 2024
Inventors:
Neil P. KING, David BAKER, Brooke FIALA, Lance Joseph STEWART, Laurent PEREZ, Antonio LANZAVECCHIA, Jessica MARCANDALLI
Abstract: X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.
Type:
Application
Filed:
August 19, 2023
Publication date:
May 9, 2024
Applicants:
Trellis Bioscience, Inc., The Regents of the University of California
Inventors:
Rebecca DUBOIS, Stas FEDECHKIN, Lawrence M. KAUVAR
Abstract: This disclosure relates to the field of molecular biology. Provided are novel genes that encode pesticidal proteins. These pesticidal proteins and the nucleic acid sequences that encode them are useful in preparing pesticidal formulations and in the production of transgenic pest-resistant plants. Methods to create or alter pesticidal proteins are provided for altered or enhanced pesticidal activity.
Type:
Application
Filed:
December 19, 2023
Publication date:
May 9, 2024
Applicant:
PIONEER HI-BRED INTERNATIONAL, INC.
Inventors:
ELLAINE ANNE MARIANO FOX, NAGA KISHORE KAKANI, KAY WALTER, TAKASHI YAMAMOTO, YI ZHENG
Abstract: The present disclosure relates to methods for producing recombinant proteins, as well as compositions used in and produced by such methods. Specifically, the present disclosure relates to methods for producing high secreted yields of recombinant proteins, and the compositions provided herein include expression constructs, recombinant vectors, and recombinant host cells that comprise polynucleotide sequences encoding proteins operably linked to recombinant secretion signals that comprise the leader peptide of the ?-mating factor (?MF) of Saccharomyces cerevisiae and a non-?MF signal peptide.
Type:
Application
Filed:
June 26, 2023
Publication date:
May 9, 2024
Inventors:
Joshua Kittleson, Thomas Stevens, Rena Hill, Carlos Gustavo Pesce, David N. Breslauer, Daniel M. Widmaier
Abstract: A protein according to an embodiment of the present application is formed by self-assembly of ferritin monomers including a ferritin monomer to which disease antigen epitope is fused. The protein exhibits excellent binding affinity to a human transferrin receptor, and thus can provide various kinds of disease antigen epitopes with different lengths to antigen-presenting cells so as to induce an immune response to the corresponding antigen.
Abstract: The present invention relates to a new whey protein hydrolysate having reduced allergenicity and retained immunogenicity. The new whey protein hydrolysate is also characterized by having a low amount of larger peptides. The invention furthermore relates to a method of preparing the new whey protein hydrolysates, uses of the new whey protein hydrolysates and food products comprising this new whey protein hydrolysate.
Type:
Application
Filed:
March 2, 2022
Publication date:
May 9, 2024
Inventors:
Hans Peter Sørensen, Hans Bertelsen, Søren Klitgaard, Lotte Neergaard Jacobsen, Ditte Møller Nielsen
Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.
Abstract: The present disclosure relates to a nucleic acid encoding human HGF and use thereof. The nucleic acid comprises one or more open reading frames (ORFs). The ORF nucleic acid sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 97%, at least 98%, at least 99% or 100% identical to the nucleic acid sequence of SEQ ID NOs: 21-31. The present disclosure provides a nucleic acid encoding human HGF, as well as a nucleic acid construct, a vector, a cell and a drug which comprise the nucleic acid. The nucleic acid has a protein expression level superior to that of a natural sequence.
Type:
Application
Filed:
March 13, 2023
Publication date:
May 9, 2024
Inventors:
Kai Wang, Jiayan Lang, Shaoli Liu, Zihang Pan, Weijing Kong, Andong Liu
Abstract: A novel interleukin-18 (IL-18) variant and a pharmaceutical composition using the same, which relates to a human IL-18 variant including (i) mutations of cysteine at positions 38, 68, 76, and 127 into serine and (ii) mutations of glutamic acid at position 6 and lysine at position 53 into alanine relative to an amino acid sequence of wild-type human IL-18, where the variant further includes (iii) at least one additional mutation, and a pharmaceutical composition containing the human IL-18 variant.
Type:
Application
Filed:
February 9, 2022
Publication date:
May 9, 2024
Applicants:
NAGASAKI UNIVERSITY, Foundation for Biomedical Research and Innovation at Kobe, National Institutes for Quantum Science and Technology
Abstract: The present invention is directed to compositions of novel, non-naturally occurring IL-12 variants, homodimeric IL-12 Fc fusion proteins, and heterodimeric IL-12 Fc fusion proteins, as well as methods of making and using such compositions.
Abstract: Applications of different configurations of novel glucagon peptide 1 with fatty acid modification or nonmodification in the treatment of T2D or the pancreas protection are provided. The dimer of the present disclosure is formed by two identical cysteine-containing GLP-1 monomers through a disulfide bond. The H-like GLP-1 homodimer (disulfide bond is inside chains) showed remarkable increase in hypoglycemic duration without reducing specific activity. The GLP-1 dimer provided has an in-vivo effective duration of up to 19 days, which significantly prolonged compared with that of the positive control drug Liraglutide with 3 days of effective duration, or thereby greatly promoting the technical advancement in long-acting GLP-1 drugs and facilitating their clinical applications and business. Meanwhile the U-like homodimer (disulfide bond is at the C-terminus) does not affect blood glucose, but can obviously protect pancreatic exocrine cells such as acini and ducts, and improve pancreas function.
Abstract: A directed chemical conjugate of a glucagon-like peptide-2 mutant, and a use thereof are provided. The glucagon-like peptide-2 mutant is based on the human glucagon-like peptide-2 through multiple site mutations and carboxy terminus extensions. By introducing a targeted chemical modification site, the glucagon-like peptide-2 mutant has biological activities consistent with the natural human glucagon-like peptide-2, and meanwhile, the half-life period in vivo is significantly prolonged, and the administration frequency is reduced, thereby achieving the purpose of treating or preventing short intestinal syndrome, intestinal mucosa injury caused by chemotherapy medicaments or radioactive treatment factors, ulcerative enteritis, chronic enteritis and non-inflammatory bowel injury disease.
Type:
Application
Filed:
January 19, 2024
Publication date:
May 9, 2024
Applicant:
PEG-BIO BIOPHARM CO.,LTD.(CHONGQING)
Inventors:
Kai FAN, Yongliang PENG, Qing CHEN, Qi ZHANG, Yong HE, Xiaolan QIN, Jie SU, Xin MEI, Wenjie ZHAO
Abstract: A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.
Abstract: Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: and pharmaceutical compositions comprising the prodrugs.
Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
Abstract: Disclosed herein are genome-edited invariant natural killer T (iNKT) cells and methods of immunotherapy using them. In particular, the disclosure relates to engineered chimeric antigen receptor (CAR)-bearing INKT cells (CAR-iNKTs) and methods of using the same for the treatment of cancer.
Type:
Application
Filed:
June 23, 2023
Publication date:
May 9, 2024
Inventors:
John DiPersio, Matthew Cooper, Julie O'Neal
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
January 19, 2024
Publication date:
May 9, 2024
Inventors:
Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
January 19, 2024
Publication date:
May 9, 2024
Inventors:
Jens HUKELMANN, Heiko SCHUSTER, Lena WULLKOPF, Christoph SCHRAEDER, Jens FRITSCHE, Daniel Johannes KOWALEWSKI, Michael ROEMER, Oliver SCHOOR
Abstract: The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.
Type:
Application
Filed:
November 21, 2023
Publication date:
May 9, 2024
Inventors:
Liselotte BRIX, Henrik PEDERSEN, Tina JAKOBSEN, Jørgen SCHØLLER, Jesper LOHSE, Katja BRUNSTEDT, Kivin JACOBSEN